- Home
- ARQT vs CNMD Comparison
ARQT vs CNMD Comparison
Compare ARQT & CNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- CNMD
- Stock Information
- Founded
- ARQT 2016
- CNMD 1970
- Country
- ARQT United States
- CNMD United States
- Employees
- ARQT N/A
- CNMD N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- CNMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ARQT Health Care
- CNMD Health Care
- Exchange
- ARQT Nasdaq
- CNMD Nasdaq
- Market Cap
- ARQT 1.7B
- CNMD 1.7B
- IPO Year
- ARQT 2020
- CNMD 1987
- Fundamental
- Price
- ARQT $13.89
- CNMD $54.09
- Analyst Decision
- ARQT Strong Buy
- CNMD Hold
- Analyst Count
- ARQT 6
- CNMD 5
- Target Price
- ARQT $18.80
- CNMD $62.20
- AVG Volume (30 Days)
- ARQT 1.9M
- CNMD 388.5K
- Earning Date
- ARQT 08-13-2025
- CNMD 07-30-2025
- Dividend Yield
- ARQT N/A
- CNMD 1.46%
- EPS Growth
- ARQT N/A
- CNMD 46.38
- EPS
- ARQT N/A
- CNMD 3.81
- Revenue
- ARQT $212,819,000.00
- CNMD $1,315,998,000.00
- Revenue This Year
- ARQT $61.15
- CNMD $6.27
- Revenue Next Year
- ARQT $37.98
- CNMD $5.62
- P/E Ratio
- ARQT N/A
- CNMD $14.38
- Revenue Growth
- ARQT 100.03
- CNMD 4.32
- 52 Week Low
- ARQT $7.86
- CNMD $46.00
- 52 Week High
- ARQT $17.75
- CNMD $78.19
- Technical
- Relative Strength Index (RSI)
- ARQT 51.91
- CNMD 48.76
- Support Level
- ARQT $13.47
- CNMD $51.43
- Resistance Level
- ARQT $14.69
- CNMD $53.05
- Average True Range (ATR)
- ARQT 0.63
- CNMD 1.66
- MACD
- ARQT 0.05
- CNMD -0.06
- Stochastic Oscillator
- ARQT 68.53
- CNMD 37.73
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.